TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding TScan Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 28 | 28 | 0 |
| Shares | 9.52M | 9.67M | +148.2K (+1.6%) |
| Value | $14.8M | $20.3M | +$5.52M (+37.3%) |
New holders (3)
Institutions that held TScan Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Simplify Asset Management Inc. | 546,916 | $1.15M | 0.21% |
| Waldron Private Wealth LLC | 10,000 | $21.0K | 0.00% |
| Advisor Group Holdings, Inc. | 1 | $2 | 0.00% |
Sold out (3)
Institutions that held TScan Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Tang Capital Management LLC | 514,655 | $797.7K |
| Millennium Management LLC | 19,244 | $31.0K |
| Prudential Financial Inc | 12,800 | $20.9K |